A peroxisome proliferator-activated receptor-alpha activator induces renal CYP2C23 activity and protects from angiotensin II-induced renal injury.

[1]  D. Zeldin,et al.  Salt-Sensitive Hypertension After Exposure to Angiotensin Is Associated With Inability to Upregulate Renal Epoxygenases , 2003, Hypertension.

[2]  M. Taskinen,et al.  Relationships Between Low-Density Lipoprotein Particle Size, Plasma Lipoproteins, and Progression of Coronary Artery Disease: The Diabetes Atherosclerosis Intervention Study (DAIS) , 2003, Circulation.

[3]  E. Schiffrin,et al.  PPARα Activator Effects on Ang II–Induced Vascular Oxidative Stress and Inflammation , 2002 .

[4]  M. Zenke,et al.  Immunosuppressive treatment protects against angiotensin II-induced renal damage. , 2002, The American journal of pathology.

[5]  A. Wierzbicki.  Lipid lowering: another method of reducing blood pressure? , 2002, Journal of Human Hypertension.

[6]  Eric F. Johnson,et al.  The CYP4A Isoforms Hydroxylate Epoxyeicosatrienoic Acids to Form High Affinity Peroxisome Proliferator-activated Receptor Ligands* , 2002, The Journal of Biological Chemistry.

[7]  F. Luft,et al.  P450-Dependent Arachidonic Acid Metabolism and Angiotensin II–Induced Renal Damage , 2002, Hypertension.

[8]  W. Campbell,et al.  What is new in endothelium-derived hyperpolarizing factors? , 2002, Current opinion in nephrology and hypertension.

[9]  M. Gollasch,et al.  Cytochrome P450-Dependent Eicosapentaenoic Acid Metabolites Are Novel BK Channel Activators , 2002, Hypertension.

[10]  B. Hammock,et al.  Soluble Epoxide Hydrolase Inhibition Lowers Arterial Blood Pressure in Angiotensin II Hypertension , 2002, Hypertension.

[11]  E. Schiffrin,et al.  PPARalpha activator effects on Ang II-induced vascular oxidative stress and inflammation. , 2002, Hypertension.

[12]  R. Roman,et al.  P-450 metabolites of arachidonic acid in the control of cardiovascular function. , 2002, Physiological reviews.

[13]  D. Zeldin.  Epoxygenase Pathways of Arachidonic Acid Metabolism* , 2001, The Journal of Biological Chemistry.

[14]  D. Ganten,et al.  Aspirin inhibits NF‐κB and protects from angiotensin II‐induced organ damage , 2001 .

[15]  L. Brass,et al.  Reduction in Stroke With Gemfibrozil in Men With Coronary Heart Disease and Low HDL Cholesterol: The Veterans Affairs HDL Intervention Trial (VA-HIT) , 2001, Circulation.

[16]  B. Staels,et al.  Peroxisome proliferator-activated receptors in inflammation control. , 2001, The Journal of endocrinology.

[17]  A. Van der Laarse,et al.  Bezafibrate reduces heart rate and blood pressure in patients with hypertriglyceridemia , 2000, Journal of hypertension.

[18]  D. Ganten,et al.  Aspirin inhibits NF-kappaB and protects from angiotensin II-induced organ damage. , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[19]  Fan Zhang,et al.  CYP4A1 antisense oligonucleotide reduces mesenteric vascular reactivity and blood pressure in SHR. , 2001, American journal of physiology. Regulatory, integrative and comparative physiology.

[20]  J. Imig.  Eicosanoid regulation of the renal vasculature. , 2000, American journal of physiology. Renal physiology.

[21]  B. Staels,et al.  Induction of IκBα Expression as a Mechanism Contributing to the Anti-inflammatory Activities of Peroxisome Proliferator-activated Receptor-α Activators* , 2000, The Journal of Biological Chemistry.

[22]  J. Sieradzki,et al.  Effects of comicronised fenofibrate on lipid and insulin sensitivity in patients with polymetabolic syndrome X , 2000, European Journal of Clinical Investigation.

[23]  F. Luft,et al.  Cytochrome P450-Dependent Renal Arachidonic Acid Metabolism in Desoxycorticosterone Acetate-Salt Hypertensive Mice , 2000, Hypertension.

[24]  D. Ganten,et al.  Angiotensin II (AT(1)) receptor blockade reduces vascular tissue factor in angiotensin II-induced cardiac vasculopathy. , 2000, The American journal of pathology.

[25]  T W Wilson,et al.  Fenofibrate lowers blood pressure in two genetic models of hypertension. , 2000, Canadian journal of physiology and pharmacology.

[26]  J. Mcgiff,et al.  Is EDHF an epoxyeicosatrienoic acid? , 2000, Trends in pharmacological sciences.

[27]  D. Ganten,et al.  Blood pressure-independent effects in rats with human renin and angiotensinogen genes. , 2000, Hypertension.

[28]  J. Falck,et al.  Cytochrome P450 and arachidonic acid bioactivation. Molecular and functional properties of the arachidonate monooxygenase. , 2000, Journal of lipid research.

[29]  B. Staels,et al.  Induction of IkappaBalpha expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferator-activated receptor-alpha activators. , 2000, The Journal of biological chemistry.

[30]  R. Busse,et al.  Cytochrome P450 2C is an EDHF synthase in coronary arteries , 1999, Nature.

[31]  V. Holla,et al.  The kidney cytochrome P-450 2C23 arachidonic acid epoxygenase is upregulated during dietary salt loading. , 1999, The Journal of clinical investigation.

[32]  J. Mcgiff,et al.  20-HETE and the kidney: resolution of old problems and new beginnings. , 1999, The American journal of physiology.

[33]  K. Ley,et al.  Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. , 1999, Science.

[34]  R. Busse,et al.  Proinflammatory mediators chronically downregulate the formation of the endothelium-derived hyperpolarizing factor in arteries via a nitric oxide/cyclic GMP-dependent mechanism. , 1999, Circulation.

[35]  L. Rosenfeld,et al.  Endothelin-1 and CYP450 arachidonate metabolites interact to promote tissue injury in DOCA-salt hypertension. , 1999, American journal of physiology. Regulatory, integrative and comparative physiology.

[36]  W. Koenig,et al.  Activation of human aortic smooth-muscle cells is inhibited by PPARα but not by PPARγ activators , 1998, Nature.

[37]  W. Koenig,et al.  Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. , 1998, Nature.

[38]  K. Takeuchi,et al.  Possible role of P-450 metabolite of arachidonic acid in vasodilator mechanism of angiotensin II type 2 receptor in the isolated microperfused rabbit afferent arteriole. , 1997, The Journal of clinical investigation.

[39]  R. Roman,et al.  Renal P450 metabolites of arachidonic acid and the development of hypertension in Dahl salt-sensitive rats. , 1997, American journal of hypertension.

[40]  K. Griffin,et al.  Role of the peroxisome proliferator‐activated receptor in cytochrome P450 4A gene regulation , 1996, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[41]  A. Hamsten,et al.  Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients , 1996, The Lancet.

[42]  T. Cresteil,et al.  Gene structure and promoter analysis of the rat constitutive CYP2C23 gene. , 1995, DNA and cell biology.

[43]  H. Jacobson,et al.  Experimental and/or genetically controlled alterations of the renal microsomal cytochrome P450 epoxygenase induce hypertension in rats fed a high salt diet. , 1994, The Journal of clinical investigation.

[44]  R. Roman,et al.  Clofibrate prevents the development of hypertension in Dahl salt-sensitive rats. , 1993, Hypertension.

[45]  J. Falck,et al.  Synthesis of epoxyeicosatrienoic acids and heteroatom analogs. , 1990, Methods in enzymology.